WASHINGTON: BioNTech of Germany and the US pharmaceutical giant Pfizer reported positive preliminary results on Wednesday from a joint project to develop a coronavirus vaccine.
Known as BNT162b1, it produces antibody responses at or above the levels seen in any convalescent serum - blood from people who have recovered - at relatively low doses, according to BioNTech CEO Ugur Sahin.
The preliminary data come from a so-called phase 1/2 trial that aimed to show the vaccine is not toxic and triggers an immune system response to prepare the body to fight off the virus. Of 45 people aged 18 to 55 who took part in the trial, most received two doses, 21 days apart, of the vaccine or a placebo.
Comments
Comments are closed.